PL3465214T3 - Sposoby przewidywania korzyści terapeutycznej terapii anty-cd19 u pacjentów - Google Patents

Sposoby przewidywania korzyści terapeutycznej terapii anty-cd19 u pacjentów

Info

Publication number: PL3465214T3
Authority: PL; Poland
Prior art keywords: predicting; therapy; patients; methods; therapeutic benefits
Prior art date: 2016-05-30

Application number

PL17728484T

Other languages

English (en)

Inventor

Jan Endell

Mark Winderlich

Rainer Boxhammer

Original Assignee

Morphosys Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-30

Filing date

2017-05-30

Publication date

2021-12-20

2017-05-30 Application filed by Morphosys Ag filed Critical Morphosys Ag

2021-12-20 Publication of PL3465214T3 publication Critical patent/PL3465214T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Organic Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL17728484T 2016-05-30 2017-05-30 Sposoby przewidywania korzyści terapeutycznej terapii anty-cd19 u pacjentów PL3465214T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP16171885		2016-05-30
EP17728484.1A EP3465214B1 (en)	2016-05-30	2017-05-30	Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
PCT/EP2017/063045 WO2017207574A1 (en)	2016-05-30	2017-05-30	Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Publications (1)

Publication Number	Publication Date
PL3465214T3 true PL3465214T3 (pl)	2021-12-20

Family

ID=56116221

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL17728484T PL3465214T3 (pl)	2016-05-30	2017-05-30	Sposoby przewidywania korzyści terapeutycznej terapii anty-cd19 u pacjentów
PL21170716.1T PL3916392T3 (pl)	2016-05-30	2017-05-30	Sposoby przewidywania korzyści terapeutycznej terapii anty-cd19 u pacjentów

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL21170716.1T PL3916392T3 (pl)	2016-05-30	2017-05-30	Sposoby przewidywania korzyści terapeutycznej terapii anty-cd19 u pacjentów

Country Status (27)

Country	Link
US (2)	US20190195879A1 (pl)
EP (2)	EP3465214B1 (pl)
JP (2)	JP7066639B2 (pl)
KR (1)	KR102416144B1 (pl)
CN (2)	CN109313194B (pl)
AU (1)	AU2017272608B2 (pl)
BR (1)	BR112018074603A2 (pl)
CY (1)	CY1124768T1 (pl)
DK (2)	DK3916392T3 (pl)
EA (1)	EA201892542A1 (pl)
ES (2)	ES2981046T3 (pl)
FI (1)	FI3916392T3 (pl)
HR (2)	HRP20210938T1 (pl)
HU (2)	HUE054860T2 (pl)
IL (1)	IL263103B2 (pl)
LT (2)	LT3465214T (pl)
MA (2)	MA57021B1 (pl)
MD (2)	MD3465214T2 (pl)
MX (2)	MX388502B (pl)
PL (2)	PL3465214T3 (pl)
PT (2)	PT3916392T (pl)
RS (2)	RS65540B1 (pl)
SG (2)	SG10201911958SA (pl)
SI (2)	SI3916392T1 (pl)
SM (2)	SMT202100291T1 (pl)
WO (1)	WO2017207574A1 (pl)
ZA (2)	ZA201808647B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3954388A1 (en)	2015-08-21	2022-02-16	MorphoSys AG	Combinations and uses thereof
IL320372A (en)	2016-10-28	2025-06-01	Morphosys Ag	Combination of anti-CD19 antibody with BCL-2 inhibitor and uses thereof
KR20200030337A (ko)	2018-09-12	2020-03-20	주식회사 녹십자랩셀	종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
SG11202111343TA (en) *	2019-05-03	2021-11-29	Morphosys Ag	Anti-cd19 therapy in patients having a limited number of nk cells
PH12022551008A1 (en) *	2019-10-31	2023-03-20	Morphosys Ag	Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
KR20220104176A (ko) *	2019-10-31	2022-07-26	모르포시스 아게	순차적 항-cd19 요법
CA3204063A1 (en) *	2020-12-04	2022-06-09	Morphosys Ag	Anti-cd19 combination therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69939939D1 (de) *	1998-08-11	2009-01-02	Idec Pharma Corp	Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
ATE450529T1 (de)	2001-02-27	2009-12-15	Governement Of The United Stat	Analoga von thalidomid als angiogeneseinhibitoren
WO2005016326A2 (en)	2003-07-11	2005-02-24	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Analogs of thalidomide as potential angiogenesis inhibitors
US7902338B2 (en)	2003-07-31	2011-03-08	Immunomedics, Inc.	Anti-CD19 antibodies
EP2216342B1 (en)	2003-07-31	2015-04-22	Immunomedics, Inc.	Anti-CD19 antibodies
KR101289537B1 (ko) *	2005-02-15	2013-07-31	듀크 유니버시티	항-ｃｄ19 항체 및 종양학에서 이의 용도
KR20080032097A (ko)	2005-06-20	2008-04-14	메다렉스, 인코포레이티드	씨디19 항체 및 그의 용도
DK2270050T3 (da)	2005-12-30	2013-08-12	Merck Patent Gmbh	Anti-CD19-antistoffer med nedsat immunogenicitet
HRP20140331T1 (hr)	2006-08-14	2014-05-09	Xencor, Inc.	Optimizirana antitijela usmjerena na cd19
MX2009002414A (es)	2006-09-08	2009-05-20	Medimmune Llc	Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
EP2062047B1 (fr)	2006-09-13	2011-03-09	Glycode	Methode d'investigation de la reponse a un traitement par un anticorps monoclonal
EP3392273A1 (en)	2007-05-30	2018-10-24	Xencor, Inc.	Methods and compositions for inhibiting cd32b expressing cells
PT2211904T (pt)	2007-10-19	2016-11-02	Seattle Genetics Inc	Agentes de ligação a cd19 e seus usos
EP2398829A2 (en)	2009-02-23	2011-12-28	Glenmark Pharmaceuticals S.A.	Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en)	2010-05-26	2011-12-01	Roche Glycart Ag	Antibodies against cd19 and uses thereof
EP2409993A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
WO2012067981A1 (en)	2010-11-15	2012-05-24	Medimmune, Llc	Combination therapy for b cell lymphomas
EP2524929A1 (en)	2011-05-17	2012-11-21	Sanofi	Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
KR102117202B1 (ko) *	2011-08-16	2020-06-01	모르포시스 아게	항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
MX354479B (es)	2011-08-16	2018-03-07	Morphosys Ag	Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
EP2791165A4 (en) *	2011-12-12	2015-08-05	Pikamab Inc	PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY
CA2935748A1 (en) *	2014-02-25	2015-09-03	Immunomedics, Inc.	Humanized rfb4 anti-cd22 antibody
EP3157553A4 (en) *	2014-06-16	2018-02-28	Xencor, Inc.	Treatment for chronic lymphocytic leukemia (cll)
US10969391B2 (en) *	2014-07-11	2021-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing hematological cancers

2017
- 2017-05-30 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 HR HRP20240670TT patent/HRP20240670T1/hr unknown
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 PL PL21170716.1T patent/PL3916392T3/pl unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 SM SM20210291T patent/SMT202100291T1/it unknown
- 2017-05-30 ES ES21170716T patent/ES2981046T3/es active Active
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 SM SM20240204T patent/SMT202400204T1/it unknown
- 2017-05-30 SI SI201731527T patent/SI3916392T1/sl unknown
- 2017-05-30 MD MDE20220770T patent/MD3916392T2/ro unknown
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/en active Active
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active Active
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/en active Active
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 MX MX2018014702A patent/MX388502B/es unknown
- 2017-05-30 CN CN202211271570.5A patent/CN115932265A/zh active Pending
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 HU HUE21170716A patent/HUE067450T2/hu unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/en not_active Ceased
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 BR BR112018074603-7A patent/BR112018074603A2/pt active Search and Examination
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
2021
- 2021-01-15 ZA ZA2021/00296A patent/ZA202100296B/en unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US20220283166A1/en active Pending

Also Published As

Publication number	Publication date
AU2017272608A1 (en)	2018-12-06
MX2021014963A (es)	2022-02-24
MA57021B1 (fr)	2024-05-31
SG10201911958SA (en)	2020-02-27
SMT202100291T1 (it)	2021-07-12
AU2017272608B2 (en)	2023-08-10
CN109313194A (zh)	2019-02-05
PL3916392T3 (pl)	2024-09-23
JP7511806B2 (ja)	2024-07-08
SG11201810159TA (en)	2018-12-28
SI3465214T1 (sl)	2021-12-31
SI3916392T1 (sl)	2024-10-30
KR20190013980A (ko)	2019-02-11
EA201892542A1 (ru)	2019-06-28
EP3916392A1 (en)	2021-12-01
ES2878156T3 (es)	2021-11-18
EP3465214B1 (en)	2021-04-28
BR112018074603A2 (pt)	2019-03-19
IL263103A (en)	2018-12-31
ZA202100296B (en)	2025-05-28
EP3465214A1 (en)	2019-04-10
HRP20210938T1 (hr)	2021-09-03
RS65540B1 (sr)	2024-06-28
JP2019519770A (ja)	2019-07-11
MA45124B1 (fr)	2021-05-31
ES2981046T3 (es)	2024-10-07
HRP20240670T1 (hr)	2024-09-27
NZ748468A (en)	2025-05-30
RS62155B1 (sr)	2021-08-31
PT3465214T (pt)	2021-06-30
IL263103B1 (en)	2023-06-01
LT3916392T (lt)	2024-08-26
JP2022119764A (ja)	2022-08-17
EP3916392B1 (en)	2024-05-01
MD3916392T2 (ro)	2024-10-31
PT3916392T (pt)	2024-06-04
WO2017207574A1 (en)	2017-12-07
CN109313194B (zh)	2022-11-04
CN115932265A (zh)	2023-04-07
US20220283166A1 (en)	2022-09-08
HUE054860T2 (hu)	2021-10-28
SMT202400204T1 (it)	2024-09-16
FI3916392T3 (fi)	2024-06-03
MX2018014702A (es)	2019-10-02
US20190195879A1 (en)	2019-06-27
IL263103B2 (en)	2023-10-01
JP7066639B2 (ja)	2022-05-13
DK3916392T3 (da)	2024-05-21
HUE067450T2 (hu)	2024-10-28
LT3465214T (lt)	2021-10-11
KR102416144B1 (ko)	2022-07-04
CY1124768T1 (el)	2022-11-25
MX388502B (es)	2025-03-20
MA45124A (fr)	2017-12-07
DK3465214T3 (da)	2021-05-31
ZA201808647B (en)	2021-05-26
CA3025823A1 (en)	2017-12-07
MD3465214T2 (ro)	2021-09-30

Publication	Publication Date	Title
IL261422A (en)	2018-10-31	Therapeutic and diagnostic methods for cancer
EP3691534C0 (en)	2023-11-29	ULTRASONIC THERAPY
PL3426271T3 (pl)	2025-11-24	Sposoby leczenia guzów litych terapią skojarzoną
PL3303632T3 (pl)	2020-07-13	Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
PL3600309T3 (pl)	2022-11-07	Skojarzenia terapeutyczne do leczenia chorób wątroby
LT3283527T (lt)	2021-03-25	Kompleksinė terapija vėžio gydymui
DK3294770T3 (da)	2020-12-07	Terapeutiske og diagnostiske fremgangsmåder til cancer
IL262211A (en)	2018-11-29	Gene therapy for treating mucopolysaccharidosis type ii
HUE059662T2 (hu)	2022-12-28	Eljárás terápiás immunsejtek hatékonyságának fokozására
DK3283106T3 (da)	2022-01-10	Terapeutiske antistoffer og anvendelser deraf
GB201517215D0 (en)	2015-11-11	Use of cannabinoids in the treatment of inflammatory skin diseases
DK2964327T3 (da)	2021-12-06	Anordninger og fremgangsmåder til multifokal ultralydsterapi
IL263103A (en)	2018-12-31	Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HRP20181109T1 (hr)	2018-11-02	Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
IL251530B (en)	2019-10-31	Use of cannabinoids in the treatment of degenerative skeletal muscle diseases
BR112017002074A2 (pt)	2018-07-03	vestuário e método de compressão médica terapêutica
KR20180084747A (ko)	2018-07-25	Galgt2 유전자 치료 방법 및 물질
DK3149049T3 (da)	2023-01-23	Il-22 til anvendelse til behandling af stofskiftesygdomme
HUE053648T2 (hu)	2021-07-28	Gyógyászati kombinációk rák kezelésére
MA50358A (fr)	2020-08-19	Sémaglutide en thérapie médicale
HUE054998T2 (hu)	2021-10-28	Kombinációs terápiák emlõrák kezelésében való alkalmazásra
DK3615502T3 (da)	2023-09-25	Terapeutiske forbindelser og fremgangsmåder
EP3585267A4 (en)	2021-01-06	DOPPLER GUIDED ULTRASONIC THERAPY
HUE067047T2 (hu)	2024-09-28	Humán antitest aggrekanáz típusú ADAMTS specieszek ellen aggrekanázzal kapcsolatos betegségek terápiájára
PL3377061T3 (pl)	2021-07-19	Mirabegron do leczenia chorób siatkówki